Alexandra V. Tarakanova

Alexandra V. Tarakanova

Auto-generated profile, based on publicly available information

Alexandra V. Tarakanova

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology, Ministry of Health of Russia

Research Focus & Metrics

Academic Career Length

5Years (2022-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
4 April 2025 in Burdenko's Journal of Neurosurgery
Verified
Journal Article
Closed access
ASA.V. Sanakoeva
A.V. Sanakoeva
ASA.E. Samarin
A.E. Samarin
EKE.I. Konopleva
E.I. Konopleva
ATA.V. Tarakanova
A.V. Tarakanova
ISIlya Sidorov
Ilya Sidorov
AKA.I. Karachunsky
A.I. Karachunsky
Background. Metastatic brain lesions following Ewing sarcoma of bones and soft tissues in children are extremely rare and have unfavorable prognosis. There are few publications devoted to this issue. Survival rates after craniotomy are extremely low. The authors describe a patient with metastatic form of Ewing sarcoma and two intracerebral (supra- and infratentorial) metastases. Total resection with subsequent radio- and chemotherapy were followed by stable remission for 23 months.

12 May 2023 in Pediatric Hematology/Oncology and Immunopathology
Verified
Journal Article
Open access
PDF file
ATA. V. Tarakanova
A. V. Tarakanova
DAD. S. Abramov
D. S. Abramov
APA. V. Pshonkin
A. V. Pshonkin
DKD. M. Konovalov
D. M. Konovalov
BCR::ABL/Ph-negative chronic myeloproliferative neoplasms (CMPN) in children differ from those in adults in clinical manifestations and genetic alterations. Taking into account the well-known physiology of hematopoiesis in children, it seems important to compare the histological features of CMPN in pediatric patients with the criteria for the diagnosis of these diseases in adults specified in the World Health Organization (WHO) classification. In pediatric practice, the interpretation of changes in hematopoiesis in patients with CMPN without any established driver mutation has a particular importance for differential diagnosis with secondary thrombocytosis and erythrocytosis. For our analysis, we used bone marrow trephine biopsy specimens from the biobank of the Pathology Department of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation. They had been obtained between 2016 and 2023 from 70 patients for initial histological examination. The final clinical diagnosis for these patients was CMPN. The frequency of the most common histological changes in hematopoiesis was assessed retrospectively. We compared our results with the data from the WHO classification, analysed the differences in morphological changes in the subgroups of patients with essential thrombocythemia with an established mutation or without it, assessed the relationship between the morphological changes and clinical symptoms of CMPN. The changes in hematopoiesis in children with CMPN are predominantly similar to those in adults, however there are differences in the morphology of megakaryocytes (scarcity of giant cells with hypersegmented nuclei (staghorn-like), an increased number of small and naked nuclei cells). In addition, bone marrow cellularity assessment has a low diagnostic value in differentiating between essential thrombocythemia and polycythemia vera in children. There are no differences in morphology in the subgroups of patients with essential thrombocythemia with an established mutation or without it. No statistically significant association between clinical symptoms of the disease and any of the morphological features of CMPN was found. The study was approved by the Independent Ethics Committee and the Scientific Council of the Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian Federation.

30 November 2023 in Russian Journal of Pediatric Hematology and Oncology
Verified
Journal Article
Open access
PDF file
ATA. V. Tarakanova
A. V. Tarakanova
ASA. S. Sharlai
A. S. Sharlai
ADAlexander E. Druy
Alexander E. Druy
DKD. M. Konovalov
D. M. Konovalov
Clinical heterogeneity appears to be one of the most characteristic feature of the group of peripheral neuroblastic tumors, ranging from spontaneous tumor regression to a widespread process, often resistant to multimodal therapeutic strategies. Despite significant progress in treatment, about 40 % of patients with high-risk neuroblastoma die from disease recurrence after complete response to first-line therapy. These 40 % are considered a “extremely high” risk group requiring intensification of therapeutic regimens from the time of diagnosis. Histological and molecular predictive features of this group are of high scientific and practical interest for the correct therapy.

14 February 2023 in Russian Journal of Archive of Pathology
Verified
Journal Article
Closed access
ATA.V. Tarakanova
A.V. Tarakanova
ASA.S. Sharlay
A.S. Sharlay
DKD.M. Konovalov
D.M. Konovalov
Аномалии гена FOXO1 в альвеолярной рабдомиосаркоме ассоциированы с худшим клиническим прогнозом, что определяет высокую ценность исследования статуса этого гена при выборе стратегии терапии. «Золотым стандартом» определения перестроек гена FOXO1 в настоящий момент является методика флюоресцентной in situ гибридизации (FISH). ЦЕЛЬ ИССЛЕДОВАНИЯ Изучение взаимосвязи канонической транслокации FOXO1 и иммуногистохимической экспрессии новых суррогатных маркеров в альвеолярной рабдомиосаркоме для определения их предиктивного значения. МАТЕРИАЛ И МЕТОДЫ На базе патолого-анатомического отделения НМИЦ ДГОИ им. Дмитрия Рогачева ретроспективно было изучено 139 наблюдений с диагнозом «рабдомиосаркома». В исследовании применялась технология тканевой матрицы (TMA). На срезах, полученных с TMA-блоков, была реализована методика FISH с использованием локусспецифичного зонда MetaSystems XL FOXO1 Break Apart («Metasystems», Германия). На аналогичных срезах с TMA-блоков было выполнено иммуногистохимическое исследование с антителами OLIG2 (Cell Marque Antibodies, клон 211F1.1) и MUC4 (Cell Marque Antibodies, клон 8G7). РЕЗУЛЬТАТЫ Итоговый анализ экспрессии и статистическую обработку с использованием таблицы сопряженности признаков 2×2 и точного теста Фишера прошли 111 случаев (76 — без перестройки FOXO1 и 35 — с перестройкой). Специфичность экспрессии OLIG2 и MUC4 в отношении FOXO1-перестроенной альвеолярной рабдомиосаркомы составила 85,53 и 80,26% соответственно (p<0,01). ЗАКЛЮЧЕНИЕ Настоящее исследование подтверждает высокое предиктивное значение экспрессии суррогатных маркеров OLIG2 и MUC4 в определении генетического статуса альвеолярной рабдомиосаркомы, что позволяет с высокой специфичностью предсказать выявление перестройки гена FOXO1.

26 May 2026 in Current Pediatrics
Verified
Journal Article
Closed access
ARArtemii Yuryevich Rynda
Artemii Yuryevich Rynda
LPLyudmila I. Papusha
Lyudmila I. Papusha
TATamara L. Antonevskaya
Tamara L. Antonevskaya
IVIgor N. Vorozhtsov
Igor N. Vorozhtsov
NGNikolay S. Grachev
Nikolay S. Grachev
GTGalina V. Tereshchenko
Galina V. Tereshchenko
Background. Infantile hemispheric glioma (IHG) is a glial tumor (often large sized) that often develops in utero or during infancy. Timely diagnosis is challenging due to its rarity in young children and the variability of its molecular genetic characteristics. Implementation of preoperative and intraoperative neuroimaging allows to remove the most morphologically significant areas of tumor tissue when total resection is not possible, while cytogenetic analysis allows for a definitive diagnosis. Case description. The child with intrauterine growth retardation has grade 2 cerebral ischemia and movement disorders syndrome. Neurosonography at 13 days of age has revealed large cystic lesion that was not identified as a tumor. An increase in head circumference up to 7 cm was noted at the age of 2.5 months, while neurosonography has shown enlargement of the cystic cavity in the left hemisphere, thus ventriculoperitoneal shunting was performed. Magnetic resonance imaging of the brain has revealed a large cystic and solid lesion in the left hemisphere at the age of 8 months. We used combined neuronavigation to establish the diagnosis and determine treatment tactics: preoperative positron emission tomography with [ 18 F]fluoroethyl-l-tyrosine combined with computed tomography and ultrasound and fluorescence guidance during the surgery. Tumor cytogenetic analysis was performed and confirmed the glial nature of the neoplasm. Conclusion. This case shows the complexity of IHG diagnosis and the benefits of preoperative and intraoperative neuronavigation, as well as cytogenetic testing, to establish the final diagnosis.

28 February 2025 in Pediatria. Journal named after G.N. Speransky
Verified
Journal Article
Closed access
OHOncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
Oncology And Immunology Named After Dmitry Rogachev National Scientific And Practical Center For Pediatric Hematology
APA.V. Pshonkin
A.V. Pshonkin
ABA.V. Bogdanov
A.V. Bogdanov
SPS.A. Plyasunova
S.A. Plyasunova
ATA.V. Tarakanova
A.V. Tarakanova
Data on the clinical course and treatment of polycythemia vera (PV) in children are extremely limited; the results of any treatment are currently unknown. Authors represent a clinical case report of a PV pediatric patient who has been receiving long-term cytoreductive therapy with pegylated interferon α-2a (PEG-IFN-α2a): 14 y/o male, first visit to the National Scientific and Practical Center for Pediatric Hematology, Oncology and Immunology named after Dmitry Rogachev (Moscow, Russia) in Apr., 2017 at the age of 8 y/o with pronounced changes in the hemogram. In the general blood test: an increase in hemoglobin - 175 g/l, hematocrit - 50.3%, erythrocytosis - up to 6.99x1012/l, other indicators were normal. Molecular genetic examination of bone marrow using high-throughput sequencing revealed a somatic mutation of the JAK2 gene c.1849G>T, p.Val617Phe with an allelic load of 30.23%. Based on the examination results, the patient was diagnosed with PV. PEG-IFN-α2a therapy was initiated. In total, the patient has been receiving the therapy for 7 years; according to the results of control examinations, a persistent partial clinical, hematological and molecular response is maintained throughout the treatment period. Mild adverse events were observed against the background of the therapy: grade 2 neutropenia, grade 1 increase in liver transaminases according to CTCAE v5.0. Conclusion: the use of the PEG-IFN-α2a effectively normalizes the clinical and hematological manifestations of PV in children with no significant adverse events of its use recorded so far.